On September 21, Moderna, Inc. rose 3.03% in pre-market trading, trading at $158.70 USD/share, with turnover of $16.71 million, extending its recent strong momentum.

The sustained rally is primarily driven by the landmark Phase 3 INTerpath-001 trial results for intismeran autogene, the personalized mRNA cancer vaccine co-developed with Merck. The therapy demonstrated statistically significant improvements in both recurrence-free survival and distant metastasis-free survival, marking the world's first mRNA cancer therapy to achieve positive results in a randomized Phase 3 trial, with no new safety concerns identified. The milestone data has propelled Moderna shares to more than double over the past month.

Multiple institutions have since upgraded their outlooks. Argus Research raised Moderna to Buy with a $180 price target, while Berenberg lifted its target to $100 and Barclays adjusted to $125. UBS highlighted three upcoming individualized neoantigen therapy data readouts as additional near-term catalysts, maintaining a $150 target. Meanwhile, the company completed a $2.6 billion convertible senior notes offering to fund its expanding oncology business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)